Friday - August 31, 2018

State-of-the-art technology offers improved care for patients in Taunton

Bayer and Taunton & Somerset NHS Foundation Trust have worked in partnership to redesign the macular service and improve patient care in Somerset.

In response to pressures on hospital eye service capacity, the ophthalmology team at Musgrove Park Hospital, part of Taunton & Somerset NHS Foundation Trust, has successfully implemented service improvements, which allow more patients to be seen and treated within recommended timelines. The redesign of the Macular Service was supported through a joint working project involving Bayer and Taunton & Somerset NHS Foundation Trust.

 

“Two of our biggest challenges were that our Medical Retinal service had a long waiting list which delayed time to diagnosis and follow up for many patients. Due to greater elderly population in Somerset, there is an ever increasing demand on the Macular treatment service. We also lacked the equipment to assess some of these patients appropriately on-site”, explained Mr Shantanu Gudsoorkar, Consultant Ophthalmologist, Musgrove Park Hospital, Taunton & Somerset NHS Foundation Trust, when commenting on the need for review of care delivery by the Macular Service. “We are thrilled to already be reaping the benefits from the introduction of our new imaging system and new patient pathways using virtual clinics. These improvements are ensuring that more patients are being seen in a timely manner and also reducing the need for out of area referrals.”

 

The availability of a new imaging system and a redesigned patient pathway means people with eye conditions in Taunton are now spending less time in clinic and returning home sooner than before the service improvements were introduced. In contrast to previous State-of-the-art technology offers improved care for patients in Taunton Bayer and Taunton & Somerset NHS Foundation Trust have worked in partnership to redesign the macular service and improve patient care in Somerset. cameras, the use of wide-field imaging allows quicker, wider and better acquisition of vital eye imagery. With the virtual clinic set-up and remote review of detailed images by consultants, the Taunton Macular Service is now delivering quicker appointments and diagnoses, increased on-site capacity for urgent patients and better quality of care. This widefield imaging system is hugely beneficial to patients with inflammatory eye conditions (uveitis).

 

Provisional audit data show that the virtual clinics for wet age-related macular degeneration (AMD) – a progessive condition that affects central vision – have improved the efficiency of injection clinics. Furthermore, people with diabetic macular oedema (DMO) – a diabetic eye disease which is a leading cause of blindness registration among working age adults in England and Wales1 – referred from screening are now being seen within national guidance timelines owing to the increased number of available treatment slots.

 

Commenting on Bayer’s contribution to the Taunton & Somerset NHS Foundation Trust joint working project, Amanda Cunnington, Head of Patient Access at Bayer UK, “With continued pressure on NHS capacity, we are proud to be able to partner with NHS Trusts like Taunton & Somerset to address some of the key challenges in delivering vital retinal services to those who need them most. By collaborating to develop customised approaches that meet the needs of local patients and improve their access to state-of-theart facilities, we’re able to help ophthalmology health services in delivering high quality patient care and improving patient outcomes.”

Contact:

Karen Tait

Karen.tait@bayer.com / 0118 206 3521

 

Paul Hopkins

Communications manager – Musgrove Park Hospital

Paul.hopkins@tst.nhs.uk / 01823 344 436

 

Notes to Editors

About retinal conditions

Some of the most common causes of vision loss include eye conditions such as wet AMD

and DMO.2,3 These are conditions that impact the central part of the retina at the back of

the eye, called the macula.4 They are caused by the growth of abnormal and fragile blood

vessels beneath the macula that bleed and leak causing problems with central vision.5

The macula is the part of the eye responsible for sharp, central vision which allows us to

see objects clearly, in detail, right in front of us.5

 

 

About Taunton & Somerset NHS Foundation Trust

For more information, go to https://www.tsft.nhs.uk/about-your-hospital/

 

 

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health

care and agriculture. Its products and services are designed to benefit people and

improve their quality of life. At the same time, the Group aims to create value through

innovation, growth and high earning power. Bayer is committed to the principles of

sustainable development and to its social and ethical responsibilities as a corporate

citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR

35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5

billion. For more information, go to www.bayer.co.uk

 

 

References

1. Diabetic macular oedema. Moorfields NHS. Available at:

https://www.moorfields.nhs.uk/condition/diabetic-macular-oedema (Last accessed August 2018)

2. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales:

April 2007-March 2008. Eye. 24 (2010) 16921699

3. Liew G et al. Comparison of the causes of blindness certifications in England and Wales in working age

adults (1664 years), 19992000. BMJ Open 2014;4:e004015. doi:10.1136/bmjopen-2013- 004015

4. RNIB. Age-related macular degeneration. Available at:

www.rnib.org.uk/eyehealth/eyeconditions/conditionsac/Pages/amd.aspx. (Last accessed August 2018)

5. National Eye Institute. Facts About macular Edema. Available at: https://nei.nih.gov/health/macularedema/

fact_sheet (Last accessed August 2018)

 
UKEYL03170074d / August 2018